Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-871-0761
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10,000.00
Profitability
Miscellaneous
Employees21
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions
What is Catalyst Biosciences' stock symbol?
Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."
When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?
Catalyst Biosciences shares reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.
How were Catalyst Biosciences' earnings last quarter?
Catalyst Biosciences Inc (NASDAQ:CBIO) announced its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.91) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.75) by $0.16. View Catalyst Biosciences' Earnings History.
When is Catalyst Biosciences' next earnings date?
What price target have analysts set for CBIO?
4 brokers have issued 1-year target prices for Catalyst Biosciences' stock. Their predictions range from $12.50 to $35.00. On average, they anticipate Catalyst Biosciences' share price to reach $23.8750 in the next year. This suggests a possible upside of 171.3% from the stock's current price. View Analyst Price Targets for Catalyst Biosciences.
What is the consensus analysts' recommendation for Catalyst Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Biosciences.
Has Catalyst Biosciences been receiving favorable news coverage?
Headlines about CBIO stock have been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catalyst Biosciences earned a news impact score of 0.8 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the near term.
Who are some of Catalyst Biosciences' key competitors?
Some companies that are related to Catalyst Biosciences include Theratechnologies (THERF), Emisphere Technologies (EMIS), Achillion Pharmaceuticals (ACHN), Rigel Pharmaceuticals (RIGL), Akorn (AKRX), Catalyst Pharmaceuticals (CPRX), MannKind (MNKD), Concert Pharmaceuticals (CNCE), OvaScience (OVAS), Beyondspring (BYSI), Abeona Therapeutics (ABEO), XBiotech (XBIT), OptiNose (OPTN), ImmunoGen (IMGN) and Progenics Pharmaceuticals (PGNX).
What other stocks do shareholders of Catalyst Biosciences own?
Who are Catalyst Biosciences' key executives?
Catalyst Biosciences' management team includes the folowing people:
- Dr. Nassim Usman, Pres, CEO & Director (Age 59)
- Mr. Fletcher Payne, Chief Financial Officer (Age 56)
- Dr. Howard Levy, Chief Medical Officer (Age 65)
- Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory Board
- Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations
Who are Catalyst Biosciences' major shareholders?
Catalyst Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (7.16%), BlackRock Inc. (7.09%), Dimensional Fund Advisors LP (4.25%), Dimensional Fund Advisors LP (4.25%), Prosight Management LP (3.91%) and Millennium Management LLC (2.45%). Company insiders that own Catalyst Biosciences stock include Howard Levy and James E Flynn. View Institutional Ownership Trends for Catalyst Biosciences.
Which major investors are selling Catalyst Biosciences stock?
CBIO stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Millennium Management LLC, Acadian Asset Management LLC, Bank of New York Mellon Corp and Two Sigma Advisers LP. View Insider Buying and Selling for Catalyst Biosciences.
Which major investors are buying Catalyst Biosciences stock?
CBIO stock was purchased by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Prosight Management LP, Assenagon Asset Management S.A., 22NW LP, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Bank of America Corp DE and BlackRock Inc.. View Insider Buying and Selling for Catalyst Biosciences.
How do I buy shares of Catalyst Biosciences?
Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Biosciences' stock price today?
One share of CBIO stock can currently be purchased for approximately $8.80.
How big of a company is Catalyst Biosciences?
Catalyst Biosciences has a market capitalization of $105.16 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-30,060,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe.
What is Catalyst Biosciences' official website?
How can I contact Catalyst Biosciences?
Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]
MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
